サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1513872

循環腫瘍細胞（CTC）診断薬の世界市場

Circulating Tumor Cell (CTC) Diagnostics

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
循環腫瘍細胞（CTC）診断薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

循環腫瘍細胞（CTC）診断薬の世界市場は2030年までに238億米ドルに達する見込み

2023年に114億米ドルと推定される循環腫瘍細胞（CTC）診断薬の世界市場は、分析期間2023-2030年にCAGR 11.2%で成長し、2030年には238億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDetection &EnrichmentTechnologyは、CAGR 10.8%を記録し、分析期間終了時には154億米ドルに達すると予測されます。分析技術セグメントの成長率は、分析期間中CAGR 12.7％と推定されます。

米国市場は30億米ドルと推定、中国はCAGR 10.2％で成長予測

米国の循環腫瘍細胞（CTC）診断薬市場は2023年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに36億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは10.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.0％と9.4％と予測されています。欧州では、ドイツがCAGR 7.8%で成長すると予測されています。

世界の循環腫瘍細胞（CTC）診断薬市場- 主要動向と促進要因のまとめ

循環腫瘍細胞（CTC）は、治療戦略の開発を導き、転移や再発のモニタリングに役立つ主な洞察を提供し、がんの診断と管理を進める上で極めて重要なものとなっています。リキッドバイオプシーとして知られる革新的なアプローチの一環として、CTC診断はがんの進行と治療効果を非侵襲的に評価し、腫瘍再発の早期発見を容易にします。このアプローチは、臨床血液サンプルからCTCを分離・分析するために、バイオマーカーを介するプラットフォームや高度な生化学的手法など、様々な技術を活用します。しかし、これらの技術は腫瘍細胞の不均一性にしばしば苦戦し、検出感度に課題をもたらします。このような課題にもかかわらず、CTCの列挙と分子プロファイリングはがんの予後を有意に予測することができ、患者の転帰を改善するために高感度CTC検出技術を日常臨床管理に組み込むことの重要性を強調しています。

最近の技術の進歩により、CTCを単離するための、より高感度でバイオマーカーに依存しない方法が導入され、がん予後の正確さと感度が向上しています。注目すべき開発は、表面荷電超常磁性ナノプローブの使用であり、これはワールブルグ効果に関連する生体電気現象を利用したもので、がん細胞はグルコース取り込みと乳酸分泌の上昇により、明瞭な負電荷を示します。この方法は、免疫親和性反応に依存し、CTCのすべての亜集団、特に上皮間葉転換（EMT）を受けているCTCを捕捉できない可能性がある従来の技術とは対照的です。密度ベースの分離やマイクロ流体デバイスを含むこれらの高度なアプローチは、CTC捕捉の特異性と効率を向上させ、精度と信頼性が最も重要な臨床環境において貴重なものとなっています。

CTC診断の利用が拡大している背景には、CTC分析を通じて特定された個々の患者の特徴に合わせてヘルスケア治療を調整する、より広範な精密医療のパラダイムへの統合があります。世界のがん罹患率の上昇に伴い、CTC診断のような革新的な診断法が急務となっています。CTC診断法は、患者にとって侵襲性の低い選択肢を提供し、転移の早期発見や疾患の進行のモニタリングを容易にすることで、がん管理に大きな影響を与えることができます。CTC技術の開発における学際的な協力、計算生物学の進歩、資金調達の増加、そしてヘルスケア政策の支援が、このような先進的診断ツールの採用をさらに促進しています。CTC診断がより臨床に組み込まれるようになれば、がん治療の状況は一変し、より個別化された、効果的でタイムリーな治療戦略につながることが期待されます。

調査対象企業の例（全48件）

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-7869

Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach US$23.8 Billion by 2030

The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$11.4 Billion in the year 2023, is expected to reach US$23.8 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2023-2030. Detection & EnrichmentTechnology, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$15.4 Billion by the end of the analysis period. Growth in the Analysis Technology segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.2% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Circulating Tumor Cell (CTC) Diagnostics Market - Key Trends and Drivers Summarized

Circulating tumor cells (CTCs) have become crucial in advancing cancer diagnosis and management, providing key insights that guide the development of treatment strategies and help monitor metastasis and recurrence. As part of an innovative approach known as liquid biopsy, CTC diagnostics allow for the non-invasive evaluation of cancer progression and treatment effectiveness, facilitating the early detection of tumor recurrence. This approach leverages various technologies, including biomarker-mediated platforms and advanced biochemical methods, to isolate and analyze CTCs from clinical blood samples. These technologies, however, often struggle with the heterogeneity of tumor cells, which can lead to challenges in detection sensitivity. Despite these challenges, the enumeration and molecular profiling of CTCs can significantly predict cancer prognosis, underscoring the importance of integrating sensitive CTC detection technologies into routine clinical management to enhance patient outcomes.

Recent technological advancements have introduced more sensitive, biomarker-independent methods for isolating CTCs, enhancing the accuracy and sensitivity of cancer prognosis. A notable development is the use of surface-charged superparamagnetic nanoprobes, which capitalize on the bio-electrical phenomena associated with the Warburg effect, where cancer cells exhibit a distinct negative charge due to elevated glucose uptake and lactic acid secretion. This method contrasts with traditional techniques that rely on immuno-affinity reactions and can miss capturing all subpopulations of CTCs, particularly those undergoing epithelial-to-mesenchymal transition (EMT). These advanced approaches, including density-based separation and microfluidic devices, improve the specificity and efficiency of CTC capture, making them invaluable in clinical settings where precision and reliability are paramount.

The growing utilization of CTC diagnostics is driven by their integration into the broader paradigm of precision medicine, which tailors healthcare treatments to individual patient characteristics identified through CTC analysis. With the global rise in cancer incidence, there is a pressing need for innovative diagnostic methods like CTC diagnostics, which offer less invasive options for patients and can significantly impact cancer management by facilitating the early detection of metastasis and monitoring disease progression. Interdisciplinary collaboration in the development of CTC technologies, advancements in computational biology, increased funding, and supportive healthcare policies are further catalyzing the adoption of these advanced diagnostic tools. As CTC diagnostics become more integrated into clinical practice, they promise to transform the landscape of cancer treatment, leading to more personalized, effective, and timely therapeutic strategies.

Select Competitors (Total 48 Featured) -

  • ApoCell, Inc.
  • Biocep Ltd.
  • Biocept, Inc.
  • Biofluidica Microtechnologies LLC
  • Celltraffix Inc.
  • Clearbridge Biomedics
  • Creatv Microtech, Inc.
  • Cynvenio Biosystems, Inc.
  • Fluxion Biosciences, Inc.
  • Ikonisys, Inc.
  • IVDiagnostics, Inc.
  • Janssen Diagnostics LLC
  • QIAGEN Hannover GmbH
  • Rarecells Sas
  • Screencell
  • Stemcell Technologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cancer Worldwide: Propels Growth in Circulating Tumor Cell (CTC) Diagnostics as a Vital Tool for Early Detection and Monitoring
    • Technological Advancements in CTC Isolation and Analysis Techniques: Drives Adoption of High-Performance Diagnostic Platforms
    • Rising Demand for Personalized Medicine: Throws the Spotlight On CTC Diagnostics for Tailored Treatment Strategies
    • Regulatory Shifts Towards Companion Diagnostics: Strengthens Business Case for CTC Testing in Treatment Decision-making
    • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
    • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
    • Emerging Applications of CTCs in Cancer Prognosis and Treatment Monitoring: Accelerates Demand for Comprehensive Diagnostic Solutions
    • Increasing Investments in Precision Oncology Research: Drives Adoption of CTC Technologies in Biomarker Discovery and Drug Development
    • Expansion of Point-of-Care Testing Capabilities: Propels Market Growth by Offering Rapid and Convenient CTC Analysis Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Circulating Tumor Cell (CTC) Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Detection & Enrichment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Direct Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Body Fluids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinical / Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • JAPAN
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • CHINA
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • EUROPE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • FRANCE
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • GERMANY
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030

IV. COMPETITION